Literature DB >> 9400811

Immunomodulatory action of G-CSF in a rat model of endotoxin-induced liver injury: an intravital microscopic analysis of Kupffer cell and leukocyte response.

B Vollmar1, S Messner, G A Wanner, T Hartung, M D Menger.   

Abstract

In contrast to the anticipation that in sepsis granulocyte colony-stimulating factor (G-CSF) would overactivate the nonspecific immune system by recruiting and priming leukocytes with consequent aggravation of inflammatory tissue lesions, recombinant (r) G-CSF pretreatment was protective in various experimental non-neutropenic models of inflammation. The mechanisms of protection, however, are not fully understood. Using intravital fluorescence microscopy, we show that rG-CSF enhances leukocyte endothelial cell interaction within the microvasculature of normal rat livers, whereas rG-CSF pretreatment of animals exposed to lipopolysaccharide (LPS) attenuates the LPS-induced leukocytic response, including stasis in sinusoids as well as rolling and adherence in postsinusoidal venules with subsequent tissue infiltration. Moreover, rG-CSF, which did not affect Kupffer cell activity in normal rat livers, reduced the immediate activation of Kupffer cells on LPS exposure, as indicated in vivo by the delayed adherence/phagocytosis of intra-arterially administered latex particles associated with attenuation of proinflammatory cytokine release (tumor necrosis factor alpha and interleukin-6). Finally, rG-CSF reduced LPS-induced nutritive perfusion failure and hepatocellular excretory dysfunction. This study provides evidence for a distinct, possibly tumor necrosis factor alpha-dependent modulation of LPS-induced cellular response within the liver by rG-CSF, thereby achieving protection against microcirculatory perfusion failure and hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400811     DOI: 10.1002/jlb.62.6.710

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

1.  Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia.

Authors:  Hoa Pham Anh Nguyen; Jinma Ren; Marilyn Butler; Henri Li; Saqib Qazi; Kamran Sadiq; Hieu Trung Dao; AiXuan Holterman
Journal:  Pediatr Surg Int       Date:  2022-04-07       Impact factor: 1.827

2.  Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery.

Authors:  Christian Schneider; Sonja von Aulock; Siegfried Zedler; Christian Schinkel; Thomas Hartung; Eugen Faist
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

3.  Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy.

Authors:  Stamatios E Theocharis; Lila J Papadimitriou; Zoi P Retsou; Alexandra P Margeli; Sotirios S Ninos; John D Papadimitriou
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

4.  Synergistic effect of erythropoietin but not G-CSF in combination with curcumin on impaired liver regeneration in rats.

Authors:  Daniel Seehofer; Ulf P Neumann; Anja Schirmeier; Jessica Carter; Si-Young Ria Cho; Andri Lederer; Nada Rayes; Michael D Menger; Andreas K Nüssler; Peter Neuhaus
Journal:  Langenbecks Arch Surg       Date:  2008-02-27       Impact factor: 3.445

5.  Complete shutdown of microvascular perfusion upon hepatic cryothermia is critically dependent on local tissue temperature.

Authors:  G Schüder; G Pistorius; M Fehringer; G Feifel; M D Menger; B Vollmar
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  The Effects of Granulocyte Colony-Stimulating Factor (G-CSF) in Pre-Clinical Models of Infection and Acute Inflammation.

Authors:  John C Marshall
Journal:  Sepsis (Boston)       Date:  1998
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.